Rakovina Therapeutics Inc.

TSXV:RKV Stock Report

Market Cap: CA$5.0m

Rakovina Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Mads Daugaard

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.1%
Management average tenureno data
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO

Mads Daugaard

no data

Tenure

Dr. Mads Daugaard, Ph D., serves as Member of Scientific Advisory Board of Hexamer Therapeutics, Inc. He serves as the President, Chief Executive Officer and Chief Scientific Officer at Rakovina Therapeuti...

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Bacha
Executive Chairman3.7yrsCA$120.00k2.09%
CA$ 103.7k
Leonard Post
Member of Scientific Advisory Board3.6yrsno datano data
Michael Liggett
Independent Director3.7yrsCA$42.50kno data
Dennis Brown
Chairman of Scientific Advisory Board & Independent Director3.7yrsCA$35.00k0.69%
CA$ 34.4k
Alfredo De Lucrezia
Independent Director5.5yrsCA$39.00k5.77%
CA$ 286.7k
Artem Cherkasov
Senior AIless than a yearno datano data
Wang Shen
Member of Scientific Advisory Board3.6yrsno datano data
Neil Sankar
Member of Scientific Advisory Board3.6yrsno datano data
Petra Hamerlik
Member of Scientific Advisory Boardless than a yearno datano data

3.6yrs

Average Tenure

64yo

Average Age

Experienced Board: RKV's board of directors are considered experienced (3.6 years average tenure).